Revive Therapeutics (CSE: RVV) announced on Wednesday that it has expanded its phase 3 clinical trial for oral drug bucillamine as a treatment for COVID-19. The firm has decided to fill a part of its patient enrollment quota in the trial with subjects outside the US, specifically from Eastern Europe such as patients in Turkey.
The middle eastern country is currently experiencing high infection rates for the pandemic disease, reporting 32,176 new daily cases on December 28, 2021 alone.
The move is also meant “to ensure a diversified patient population to support future global regulatory submissions.”
To date, the trial has screened approximately 700 subjects while no serious adverse events and safety concerns reported were reported so far.
The biotech firm is targeting to complete the study by Q1 2022 and is expected to file for Emergency Use Authorization with the US FDA following the trial’s results.
Earlier this month, the study also expanded to include the emerging Omicron variant of SARS-CoV-2 in its phase 3 clinical trial.
Revive Therapeutics last traded at $0.40 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a former client of Canacom Group, the parent company of The Deep Dive. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
